AVTX · NASDAQ
Avalo Therapeutics, Inc.
$6.73 -0.34 (-4.74%)
Company overview
Avalo Therapeutics, Inc. is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease including moderate to severe Crohn's disease and ulcerative colitis, and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of Still's disease including adult-onset Still's disease and systemic juvenile idiopathic arthritis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $361M
- Employees
- 23
- Headquarters
- Rockville, MD
- Website
- avalotx.com
- CEO
- Garry A. Neil
- Listed
- October 14, 2015
- P/E
- -1.15
- Dividend yield
- 0.00%
Company financials
- Revenue
- $59,000
- Gross profit
- $42,000
- Operating income
- -$79.2M
- EBITDA
- -$90.3M
- Net income
- -$84.7M
- EPS
- -$5.83
- Total assets
- $99.9M
- Total debt
- $2.3M
- Gross margin
- 71.19%
- Net margin
- -143,627.12%
- Earnings yield
- -86.63%
No geographic segmentation.
Showing FY 2025
AVTX
1D
NASDAQ
O7.47H7.59L6.79C7.07-0.18 (-2.55%)Vol1.13M
News